These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 9794839)

  • 1. Clinical applications of TNF-alpha in cancer.
    Lejeune FJ; Rüegg C; Liénard D
    Curr Opin Immunol; 1998 Oct; 10(5):573-80. PubMed ID: 9794839
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficiency of recombinant human TNF in human cancer therapy.
    Lejeune FJ; Liénard D; Matter M; Rüegg C
    Cancer Immun; 2006 Mar; 6():6. PubMed ID: 16551058
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of patients with melanoma of the extremity using hyperthermic isolated limb perfusion with melphalan, tumor necrosis factor, and interferon gamma: results of a tumor necrosis factor dose-escalation study.
    Fraker DL; Alexander HR; Andrich M; Rosenberg SA
    J Clin Oncol; 1996 Feb; 14(2):479-89. PubMed ID: 8636761
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of in-transit metastases from cutaneous melanoma by isolation perfusion with tumour necrosis factor-alpha (TNF-alpha), melphalan and interferon-gamma (IFN-gamma). Dose-finding experience at the National Cancer Institute of Milan.
    Vaglini M; Santinami M; Manzi R; Inglese MG; Santoro N; Persiani L; Belli F
    Melanoma Res; 1994 Mar; 4 Suppl 1():35-8. PubMed ID: 8038594
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Isolated limb perfusion with high-dose tumor necrosis factor-alpha in combination with interferon-gamma and melphalan for nonresectable extremity soft tissue sarcomas: a multicenter trial.
    Eggermont AM; Schraffordt Koops H; Liénard D; Kroon BB; van Geel AN; Hoekstra HJ; Lejeune FJ
    J Clin Oncol; 1996 Oct; 14(10):2653-65. PubMed ID: 8874324
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recombinant human tumor necrosis factor: an efficient agent for cancer treatment.
    Lejeune FJ; Rüegg C
    Bull Cancer; 2006 Aug; 93(8):E90-100. PubMed ID: 16935777
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytokine levels and systemic toxicity in patients undergoing isolated limb perfusion with high-dose tumor necrosis factor, interferon gamma, and melphalan.
    Thom AK; Alexander HR; Andrich MP; Barker WC; Rosenberg SA; Fraker DL
    J Clin Oncol; 1995 Jan; 13(1):264-73. PubMed ID: 7799030
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma.
    Lienard D; Ewalenko P; Delmotte JJ; Renard N; Lejeune FJ
    J Clin Oncol; 1992 Jan; 10(1):52-60. PubMed ID: 1727926
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Complications of combined radiotherapy and isolated limb perfusion with tumor necrosis factor alpha +/- interferon gamma and melphalan in patients with irresectable soft tissue tumors.
    Vrouenraets BC; Keus RB; Nieweg OE; Kroon BB
    J Surg Oncol; 1997 Jun; 65(2):88-94. PubMed ID: 9209519
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Efficacy of the tumor necrosis factor-alpha (rTNF-alpha) associated with interferon-gamma and chemotherapy in extracorporeal circulation in the limb in inoperable malignant melanoma, soft tissue sarcoma and epidermoid carcinoma. A 4-year experience].
    Lejeune F; Liénard D; Eggermont A; Schraffordt Koops H; Rosenkaimer F; Gérain J; Klaase J; Kroon B; Schmitz P
    Bull Cancer; 1995 Jul; 82(7):561-7. PubMed ID: 7549119
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experience.
    Eggermont AM; Schraffordt Koops H; Klausner JM; Kroon BB; Schlag PM; Liénard D; van Geel AN; Hoekstra HJ; Meller I; Nieweg OE; Kettelhack C; Ben-Ari G; Pector JC; Lejeune FJ
    Ann Surg; 1996 Dec; 224(6):756-64; discussion 764-5. PubMed ID: 8968230
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High dose recombinant tumour necrosis factor (rTNF alpha) administered by isolation perfusion for advanced tumours of the limbs: a model for biochemotherapy of cancer.
    Lejeune FJ
    Eur J Cancer; 1995 Jun; 31A(6):1009-16. PubMed ID: 7646901
    [No Abstract]   [Full Text] [Related]  

  • 13. Rapid increase in plasma tenascin-C concentration after isolated limb perfusion with high-dose tumor necrosis factor (TNF), interferon gamma (IFN gamma) and melphalan for regionally advanced tumors.
    Schienk S; Liénard D; Gerain J; Baumgartner M; Lejeune FJ; Chiquet-Ehrismann R; Rüegg C
    Int J Cancer; 1995 Nov; 63(5):665-72. PubMed ID: 7591283
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Value of isolation-perfusion of the limbs in melanomas and sarcomas].
    Lejeune F; Liénard D; Eggermont A; Schraffordt Koops H; Kroon B
    Ann Chir; 1995; 49(1):9-12. PubMed ID: 7741477
    [No Abstract]   [Full Text] [Related]  

  • 15. Synergistic effects of TNF-alpha and melphalan in an isolated limb perfusion model of rat sarcoma: a histopathological, immunohistochemical and electron microscopical study.
    Nooijen PT; Manusama ER; Eggermont AM; Schalkwijk L; Stavast J; Marquet RL; de Waal RM; Ruiter DJ
    Br J Cancer; 1996 Dec; 74(12):1908-15. PubMed ID: 8980389
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Isolation limb perfusion with tumor necrosis factor alpha and chemotherapy for advanced extremity soft tissue sarcomas.
    Eggermont AM; Schraffordt Koops H; Klausner JM; Liénard D; Kroon BB; Schlag PM; Ben-Ari G; Lejeune FJ
    Semin Oncol; 1997 Oct; 24(5):547-55. PubMed ID: 9344321
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early endothelium activation and polymorphonuclear cell invasion precede specific necrosis of human melanoma and sarcoma treated by intravascular high-dose tumour necrosis factor alpha (rTNF alpha).
    Renard N; Liénard D; Lespagnard L; Eggermont A; Heimann R; Lejeune F
    Int J Cancer; 1994 Jun; 57(5):656-63. PubMed ID: 8194873
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Isolated limb perfusion with high-dose tumor necrosis factor for extremity melanoma and sarcoma.
    Fraker DL; Alexander HR
    Important Adv Oncol; 1994; ():179-92. PubMed ID: 8206489
    [No Abstract]   [Full Text] [Related]  

  • 19. Synergistic antitumour effect of recombinant human tumour necrosis factor alpha with melphalan in isolated limb perfusion in the rat.
    Manusama ER; Nooijen PT; Stavast J; Durante NM; Marquet RL; Eggermont AM
    Br J Surg; 1996 Apr; 83(4):551-5. PubMed ID: 8665257
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Isolated perfusion of the limb with high-dose tumour necrosis factor-alpha (TNF-alpha), interferon-gamma (IFN-gamma) and melphalan for melanoma stage III. Results of a multi-centre pilot study.
    Liénard D; Eggermont AM; Schraffordt Koops H; Kroon BB; Rosenkaimer F; Autier P; Lejeune FJ
    Melanoma Res; 1994 Mar; 4 Suppl 1():21-6. PubMed ID: 8038591
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.